Comparison · NCT02540993-sae
Finerenone vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Finerenone vs Placebo: serious adverse events. Trial comparisons, record NCT02540993-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02540993-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.319 | 0.302 | 0.336 | wilson | |
| Risk in group 2 | 0.343 | 0.326 | 0.361 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0239 | -0.0484 | 0.000601 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.93 | 0.864 | 1 | log | |
| Odds ratio, group 1 over group 2 | 0.898 | 0.803 | 1 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Finerenone than on Placebo | 41.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Finerenone | Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy | 902 | 2,827 | EG000 |
| Group 2 | Placebo | Participants received matching placebo once daily in addition to standard of care therapy | 971 | 2,831 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- After the first dose of study drug up to 3 days after any temporary or permanent interruption of study drug, with an average treatment duration of 27 months
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
- NCT number
- NCT02540993
- Phases
- PHASE3
- Conditions
- Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2021-07-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02540993?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02540993-sae